Podcast
High Symptom Burden Among Patients With Advanced Upper GI Cancer Undergoing Chemotherapy
February 19, 2021
Xin Shelley Wang, MD, MPH, discusses results from a real-world study exploring PROs of symptom burden and functioning among patients with advanced esophageal, gastroesophageal junction, and gastric cancer undergoing chemotherapy.
Videos
HRQoL Low Among Young Adult Colorectal Cancer Survivors
February 04, 2021
Kimberly Miller, PhD, MPH, discusses results from a study exploring HRQoL in colorectal cancer survivors who were diagnosed before age 50.
Podcast
NCCN Guideline Adherence Improves Survival Outcomes in Anal Cancer
February 04, 2021
Priyanka Kumar, MD, discusses a recent study which analyzed adherence to the NCCN treatment guidelines for anal squamous cell carcinoma in California and the associated impacts on survival.
Videos
Real-World Outcomes of Recurrent vs De Novo Metastatic Pancreatic Cancer
February 03, 2021
Laura Miotke, MD, discusses data suggesting that patients with recurrent metastatic pancreatic adenocarcinoma have significantly better survival outcomes compared with those with de novo metastatic disease.
Conference Coverage
Tumor Mutation Burden Unlikely Biomarker for Checkpoint Inhibitor Response in CRC
February 03, 2021
Results from a real-world study show tumor mutation burden is unlikely indicative of checkpoint inhibitor response for patients with CRC, despite recent tissue-agnostic approvals.
Podcast
High Economic Burden of HCC Treated With Loco-Regional Therapies
January 27, 2021
Brian Seal, PhD, RPh, MBA discusses results from a study which examined the lines of loco-regional therapies received by patients with HCC in the US and the economic burden associated with the disease.
Videos
Post-Treatment Alpha-Fetoprotein Reduction Prognostic for Survival Outcomes in HCC
January 26, 2021
Ghassan Abou-Alfa, MD, discusses results from a study evaluating the association between post-treatment α-fetoprotein reduction and real-world outcomes in US patients with HCC.
Videos
High Costs of Pancreatic Enzyme Replacement Therapy Barrier to Medicare Beneficiary Drug Access
January 20, 2021
Arjun Gupta, MD, discusses results from a study assessing out-of-pocket and total spending on pancreatic enzyme replacement therapy under Medicare Part D.
Videos
DPYD Genotyping Cost-Effective Screening Strategy Prior to Adjuvant Chemotherapy in Colon Cancer
January 20, 2021
Gabriel Brooks, MD, MPH, discusses results from a study evaluating the cost-effectiveness of DPYD genotyping to screen for dihydropyrimidine dehydrogenase prior to adjuvant chemotherapy for colon cancer.
Conference Coverage
Weekly vs Biweekly Cetuximab for Metastatic Colorectal Cancer
January 19, 2021
Real-world study results demonstrate comparable efficacy regarding OS with weekly and biweekly cetuximab for metastatic colorectal cancer in the US.
Videos
Patients With Advanced HCC Often Do Not Receive Second-Line Therapy in Real-World Practice
January 19, 2021
Arjun Gupta, MD, discusses results from a study analyzing real-world treatment patterns and associated outcomes for the second-line treatment of advanced HCC.
Conference Coverage
Lenvatinib Effective for Unresectable HCC in the Real-World Setting
January 16, 2021
Findings from a real-world study affirm the effectiveness of first-line lenvatinib monotherapy for HCC in US clinical practice.
Conference Coverage
NCCN Guideline Adherence Associated With Improved Patient Outcomes in Anal Cancer
January 15, 2021
Treatment in concordance with NCCN guidelines for anal squamous cell carcinoma was associated with improved disease-specific and overall survival.
Conference Coverage
Atezolizumab Plus Bevacizumab Unlikely to be Cost-Effective Compared With Sorafenib for HCC
January 15, 2021
Atezolizumab plus bevacizumab is unlikely to be cost-effective compared with sorafenib for the first-line treatment of unresectable or metastatic HCC from a US payer perspective.